Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 801 results for "for merck"

This Double-Whammy Sent Merck Shares Notably Lower in September

This Double-Whammy Sent Merck Shares Notably Lower in September

MRK data by YCharts . Shares of Big Pharma Merck struggled mightily in September, ending the month lower by 7.5% according to data from S&P Capital IQ . Since August 19, Merck's stock has dropped by almost 17%, wiping out more than $27 billion in ... Nasdaq, 19 hours ago

903 images for for merck

Mideast Time, 1 day ago
Jutia Group, 15 hours ago
Dexigner, 16 hours ago
Dexigner, 16 hours ago
Dexigner, 16 hours ago
Dexigner, 16 hours ago
Dexigner, 16 hours ago
Dexigner, 16 hours ago
Dexigner, 16 hours ago
Dexigner, 16 hours ago
WA Today

US drug major Merck buys into Bionomics

Merck has bought a stake in Bionomics Photo: Fairfax The local biotechnology industry has received a significant boost to its international recognition with United States drug major Merck taking a direct slice of equity in Bionomics, a local drug ...
 WA Today2 days ago

Global and USA Biosimilar Market: Latest updates from Hospira, Sandoz, Merck, Teva, Boehringer Ingelheim...

SMi Group reports: Leading organizations in the Biosimilars Development sector will meet at SMi Group's Biosimilars and Biobetters USA 2015 the must-attend premier industry event which will take place in Iselin this November (PRWeb October 06, ...
 PRWeb3 days ago How Califf As FDA Commissioner Could Benefit Biosimilar Market  Bioresearch Online1 week ago
Monthly Prescribing Reference

Nasal Allergy Spray Currently Unavailable

Share this article: NASONEX (mometasone furoate) aqueous nasal spray by Merck & Co. Merck has issued a letter to healthcare professionals letting them know that Nasonex (mometasone furoate monohydrate) Nasal Spray 50mcg is currently out ...
 Monthly Prescribing Reference4 days ago FDA approves Keytruda for patients with metastatic NSCLC  European Pharmaceutical Review4 days ago FDA expands Merck drug's approval to treat lung cancer  Asian Age1 week ago FDA expands approval of Merck's Keytruda to lung cancer  Reuters1 week ago

Results From Merck's Phase 3 Study Of Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir In Patients With Advanced Chronic Kidney Disease Published In The Lancet

Reddit Email Print Reprint Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the publication of results from C-SURFER , the first Phase 3 1 clinical trial to investigate an all-oral, ribavirin-free chronic ...
 TheStreet.com4 days ago HCV therapy Elbasvir/grazoprevir shows sustained virologic response  European Pharmaceutical Review3 days ago
TopNews New Zealand

Kuvan rights Transferred back to BioMarin by Merck

As per an earlier agreement, BioMarin had transferred the rights to market KuvanĀ® in all territories outside the U.S., Canada and Japan to Merck Serono. Now, a settlement has been reached to return the rights to BioMarin. However, Merck still ...
 TopNews New Zealand5 days ago BioMarin Buys Kuvan Drug Rights From Merck  TheStreet.com1 week ago Merck to return Kuvan drug rights to BioMarin Pharmaceutical  Pharmaceutical Business Review1 week ago Merck Narrows Focus, Sells Therapeutic Drugs Back to BioMarin  Pharmaceutical Manufacturing Magazine1 week ago

BioMarin To Acquire Rights To Phenylketonuria (PKU) Franchise From Merck Serono

Strengthens and Expands BioMarin's Leadership Position Serving PKU Patients with Rights to Both KuvanĀ® (sapropterin dihydrochloride) and Pegvaliase Beyond North America 2016 Full-year Guidance for Kuvan Expected to be Between $320M-$350M ...
 TheStreet.com1 week ago Merck KGaA returns rights to Kuvan and pegvaliase to BioMarin; $70 - 80M in new revenue expected  TeleTrader.com1 week ago BioMarin Buys Back Kuvan Rights And Aims At Bigger Target  TeleTrader.com1 week ago

Sigma-Aldrich And Merck KGaA, Darmstadt, Germany, Making Progress Toward Completion Of Planned Acquisition

ST. LOUIS , Sept. 28, 2015 /PRNewswire/ --Sigma-Aldrich Corporation (NASDAQ: SIAL) announced today it is making progress toward closing the planned acquisition of the Company by Merck KGaA, Darmstadt, Germany.The closing is now expected within the ...
 TheStreet.com1 week ago Merck KGaA, Darmstadt, Germany, And Pfizer Announce FDA Orphan Drug Designation For Investigational Immunotherapy Avelumab In Merkel Cell Carcinoma  TheStreet.com2 weeks ago Merck and Pfizer Announce FDA Orphan Drug Designation for Investigational Immunotherapy  PharmaceuticalProcessing2 weeks ago

Merck To Hold Third-Quarter 2015 Sales And Earnings Conference Call On October 27

Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2015 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, Oct. 27. During the call, company ...
 TheStreet.com2 weeks ago US stocks continue gains as analysts predict Wall Street bounce  Malay Mail2 days ago S&P 500, Nasdaq end down as investors await earnings  SRN News3 days ago Market Wrap: Stocks Drop as 3Q Earnings Season Kicks Off  Daily Finance3 days ago
Yahoo! Finance

Apple's Printed Battery Acquisition Likely to Disappoint

- Leading companies like Apple, Merck KGaA, BASF, and Xerox have made high-profile acquisitions of start-ups in printed electronics. However, many of the companies acquired have been second-tier players, leaving more attractive acquisition or ...
 Yahoo! Finance1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less